Top 5 Drug Type | Count |
---|---|
Small molecule drug | 10 |
Proteolysis-targeting chimeras (PROTAC) | 4 |
circular RNA | 1 |
Exosomes | 1 |
Molecular glue | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Bcr-Abl inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date12 Feb 2025 |
Sponsor / Collaborator |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Chimeric Natural Killer Receptor-Universal T Cells(Fujian Medical University) | Steroid Refractory Graft Versus Host Disease More | Phase 1 |
Exosome of Mesenchymal Stem Cells(Fujian Medical University) | Multiple Organ Failure More | Clinical |
Koumine Hydrochloride | Rheumatoid Arthritis More | IND Approval |
C1206 ( HSP90 ) | Philadelphia chromosome positive chronic myelogenous leukemia More | Preclinical |
DC-BPi-11 ( BPTF ) | Leukemia More | Preclinical |